Genomic Profiling of Chronic Myelogenous Leukemia: Basic and Clinical Approach

다국어 초록 (Multilingual Abstract)

Chronic myeloid leukemia (CML) is a hematological stem cell cancer driven by BCR-ABL1 fusion protein. We review the previous and recent evidence on the significance of CML in diagnostic and clinic management. The technical monitoring of BCR-ABL1 with quantitative real time-PCR has been used in assessing patient outcome. The cytogenetic mark of CML is Philadelphia chromosome, that is formed by reciprocal chromosomal translocations between human chromosome 9 and 22, t(9:22) (q34:q11). It makes a BCR-ABL1 fusion protein with an anomaly tyrosine kinase activity that promotes the characteristic proliferation of progenitor cells in CML and acute lymphoblastic lymphoma. The targeting of BCR-ABL1 fusion kinase is the first novel paradigm of molecularly targeted curing.

참고문헌 (Reference)

1 Varma N, "Unusual clonal cytogenetic abnormalities in aplastic anemia" 49 : 256-257, 1995

2 Traxler P, "Tyrosine kinase inhibitors: from rational design to clinical trials" 21 : 499-512, 2001

3 Akard LP, "Translating trial-based molecular monitoring into clinical practice: importance of international standards and practical considerations for community practitioners" 11 : 385-395, 2011

4 Ernst T, "Transcription factor mutations in myelodysplastic/myeloproliferative neoplasms" 95 : 1473-1480, 2010

5 Li F, "The histone mark H3K36me3 regulates human DNA mismatch repair through its interaction with MutSα" 153 : 590-600, 2013

6 Calabretta B, "The biology of CML blast crisis" 103 : 4010-4022, 2004

7 Ali Soroush, "The Role of Oral Contraceptive Pills on Increased Risk of Breast Cancer in Iranian Populations: A Meta-analysis" 대한암예방학회 21 (21): 294-301, 2016

8 Movafagh A, "Secondary chromosomal abnormalities of de novo acute myeloid leukemia: a first report from the Middle East" 12 : 2991-2994, 2011

9 Damm F, "SETBP1 mutations in 658 patients with myelodysplastic syndromes, chronic myelomonocytic leukemia and secondary acute myeloid leukemias" 27 : 1401-1403, 2013

10 Laborde RR, "SETBP1 mutations in 415 patients with primary myelofibrosis or chronic myelomonocytic leukemia: independent prognostic impact in CMML" 27 : 2100-2102, 2013

11 Machova Polakova K, "Role of epigenetics in chronic myeloid leukemia" 8 : 28-36, 2013

12 Roche-Lestienne C, "RUNX1 DNA-binding mutations and RUNX1-PRDM16cryptic fusions in BCR-ABL+ leukemias are frequently associated with secondary trisomy 21 and may contribute to clonal evolution and imatinib resistance" 111 : 3735-3741, 2008

13 Itzykson R, "Prognostic score including gene mutations in chronic myelomonocytic leukemia" 31 : 2428-2436, 2013

14 Apperley JF, "Part II: management of resistance to imatinib in chronic myeloid leukaemia" 8 : 1116-1128, 2007

15 Kohlmann A, "Next-generation sequencing technology reveals a characteristic pattern of molecular mutations in 72.8% of chronic myelomonocytic leukemia by detecting frequent alterations in TET2, CBL, RAS, and RUNX1" 28 : 3858-3865, 2010

16 Gelsi-Boyer V, "Mutations of polycomb-associated gene ASXL1in myelodysplastic syndromes and chronic myelomonocytic leukaemia" 145 : 788-800, 2009

17 Carbuccia N, "Mutations of ASXL1 gene in myeloproliferative neoplasms" 23 : 2183-2186, 2009

18 Shah NP, "Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia" 2 : 117-125, 2002

19 Schmidt M, "Molecular-defined clonal evolution in patients with chronic myeloid leukemia independent of the BCR-ABL status" 28 : 2292-2299, 2014

20 Grossmann V, "Molecular profiling of chronic myelomonocytic leukemia reveals diverse mutations in ＞80% of patients with TET2and EZH2 being of high prognostic relevance" 25 : 877-879, 2011

21 Hughes TP, "Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia:an analysis from the International Randomized Study of Interferon and STI571 (IRIS)" 116 : 3758-3765, 2010

22 Rowley JD, "Letter: a new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining" 243 : 290-293, 1973

23 이경은, "Immunohistochemical Assessment of O6-Methylguanine-DNA methyltransferase (MGMT) and Its Relationship with p53 expression in Endometrial Cancers" 대한암예방학회 18 (18): 351-354, 2013

24 Rousselot P, "Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years" 109 : 58-60, 2007

25 O'Brien SG, "Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia" 348 : 994-1004, 2003

26 Kerenyi MA, "Histone demethylase Lsd1 represses hematopoietic stem and progenitor cell signatures during blood cell maturation" 2 : e00633-, 2013

27 Movafagh A, "Geographic heterogeneity of cytogenetic characteristics of acute myeloid leukemia in the early detection: a comparative study of iranian and indian adult patients" 2 : 85-89, 2009

28 Katoh M, "Functional and cancer genomics of ASXL family members" 109 : 299-306, 2013

29 Weerkamp F, "Flow cytometric immunobead assay for the detection of BCR-ABL fusion proteins in leukemia patients" 23 : 1106-1117, 2009

30 Daver N, "FLT3mutations in myelodysplastic syndrome and chronic myelomonocytic leukemia" 88 : 56-59, 2013

31 Cloos PA, "Erasing the methyl mark: histone demethylases at the center of cellular differentiation and disease" 22 : 1115-1140, 2008

32 Druker BJ, "Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells" 2 : 561-566, 1996

33 Fabarius A, "Dynamics of cytogenetic aberrations in Philadelphia chromosome positive and negative hematopoiesis during dasatinib therapy of chronic myeloid leukemia patients after imatinib failure" 92 : 834-837, 2007

34 Breccia M, "Discontinuation of imatinib therapy after achievement of complete molecular response in a Ph(+) CML patient treated while in long lasting complete cytogenetic remission (CCR) induced by interferon" 30 : 1577-1579, 2006

35 Chu S, "Detection of BCR-ABL kinase mutations in CD34＋ cells from chronic myelogenous leukemia patients in complete cytogenetic remission on imatinib mesylate treatment" 105 : 2093-2098, 2005

36 Wimmer K, "Constitutional mismatch repair-deficiency syndrome: have we so far seen only the tip of an iceberg?" 124 : 105-122, 2008

37 Abdel-Wahab O, "Concomitant analysis of EZH2 and ASXL1 mutations in myelofibrosis, chronic myelomonocytic leukemia and blast-phase myeloproliferative neoplasms" 25 : 1200-1202, 2011

38 Yamamoto M, "Clonal evolution with inv(11)(p15q22) and NUP98/DDX10 fusion gene in imatinib-resistant chronic myelogenous leukemia" 157 : 104-108, 2005

39 Oktem G, "Cancer stem cell differentiation: TGFβ1 and versican may trigger molecules for the organization of tumor spheroids" 32 : 641-649, 2014

40 Itzykson R, "An evolutionary perspective on chronic myelomonocytic leukemia" 27 : 1441-1450, 2013

41 Seabright M, "A rapid banding technique for human chromosomes" 2 : 971-972, 1971